ArticleJournal of cerebrovascular and endovascular neurosurgery2026
Mean platelet volume and clinical outcomes in patients with acute ischemic stroke: A systematic review and meta-analysis.
Article in Journal of cerebrovascular and endovascular neurosurgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveMean platelet volume (MPV) is a laboratory marker that reflects platelet activity and has been linked to a higher risk of thromboembolic events. This study aimed to evaluate MPV as a potential biomarker for clinical outcomes in acute ischemic stroke.
methodsA systematic search was conducted in PubMed, Embase, Scopus, Web of Science, and Google Scholar up to March 2024. Risk of bias was assessed using the Newcastle-Ottawa Scale. When meta-analysis was not feasible, a narrative synthesis was performed. Subgroup and sensitivity analyses were planned, and the certainty of evidence was graded using the GRADE approach.
resultsOut of 534 studies, 57 were included (10,979 patients). Higher MPV levels were associated with poor functional outcomes (modified Rankin Scale [mRS] >2) at 90 days, although with high heterogeneity (MD: 0.50; 95% CI: 0.31-0.70; I2=82%). A weak positive correlation was found between MPV and impairment measure (National Institutes of Health Stroke Scale [NIHSS]: r=0.140-0.221). MPV was also associated with mortality at 3 months (OR: 3.88) and 1 year (OR: 1.76). No significant associations were observed with one-year disability, hemorrhagic transformation, cerebral microbleeds, or in-hospital complications.
conclusionsIn summary, MPV may be associated with worse 90-day functional outcomes and mortality; however, its correlation with impairment severity measured by NIHSS was weak. Further studies are needed to establish optimal cut-off values and incorporate MPV into predictive models.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.